Ocular Hypertension And Yoga Study (OHAYS)

This study has been withdrawn prior to enrollment.
(No Funding was acquired.)
Sponsor:
Information provided by (Responsible Party):
Pamela Jeter, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01446588
First received: September 20, 2011
Last updated: May 23, 2014
Last verified: May 2014
  Purpose

The investigators aim to pilot test the efficacy of a yoga intervention designed specifically for individuals with ocular hypertension. The investigators would like to find out if a combination of breathing, postures and meditation may help to reduce intraocular pressure in the short term after each yoga session, and also long-term across an 8-week program. Subjects will participate in the yoga intervention sessions led by Dr. Pamela Jeter once a week at the investigators center, and will be asked to practice at home at least twice a week using a audio CD.


Condition Intervention
Ocular Hypertension
Sleep Disturbance
Stress
Anxiety
Depression
Behavioral: Yoga Intervention

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Ocular Hypertension And Yoga Study

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Intraocular Pressure (IOP) [ Time Frame: Change in IOP from mean baseline at 8-weeks (end of yoga intervention period) ] [ Designated as safety issue: Yes ]
    Baseline IOP measures will be obtained at two visits prior to the intervention. At each weekly visit, we will obtain two series of IOP measures about one hour apart, similar to the sequence that will be used during the weekly yoga intervention, to estimate trends over an 8-week intervention period. Post-intervention IOP will be measured at a single session one week after the yoga intervention has ended, and at a follow-up visit one month after the yoga intervention. Subjects will be masked to the IOP results until they have completed the study.


Secondary Outcome Measures:
  • Body Mass Index (BMI) (i.e. weight and height) [ Time Frame: Week 0 and week 8 ] [ Designated as safety issue: No ]
    Weight and height will be taken at baseline and Post-intervention.

  • Blood pressure [ Time Frame: once a week for a total period of 11 weeks; then one additional measure 1 month later ] [ Designated as safety issue: No ]
    Systemic blood pressure (using a digital monitor with an automated cuff) and pulse rate will be measured at baseline, at the beginning and end of each yoga class, and the two post-intervention visits.

  • Respiratory Rate (RR) [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    Respiratory rate will be measured twice for each participant to reduce within-session variability. It will be determined by counting the number of inhalations with a stethoscope for 30 seconds at rest and multiplying by two at baseline and post-intervention.

  • Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    The 19-item PSQI questionnaire will be used to gauge sleep quality over the past month. It includes both qualitative and quantitative aspects of sleep, and evaluates seven subscale dimensions of sleep quality. Measured at baseline (week 0) and immediately after the 8-week intervention.

  • Perceived Stress Scale (PSS) [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    In order to subjectively assess the degree to which respondents have appraised situations in their life to be stressful on a given day, we will administer the 14 item PSS.

  • Beck Anxiety Index (BAI) [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    The 21 item BAI will be used to measure the severity of an individual's anxiety over the past month.

  • Beck Depression Index (BDI) [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    We will use the BDI to provide a measure of severity and type of depression.

  • Positive and Negative Affect Schedule (PANAS) [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    The PANAS questionnaire consists of 10 positive affect items, which reflect one's level of pleasurable engagement with the environment, and 10 negative affect items, which are a general factor of subjective distress.

  • Vision Test/Ocular Disease Catastrophizing Scale [ Time Frame: Week 0 and Week 8 ] [ Designated as safety issue: No ]
    The Catastrophizing Scale includes 20 questions that measure the individual's state and/or trait immediately after vision tests are performed.

  • Philadelphia Mindfulness Scale (PHLMS) [ Time Frame: Week 0, Week 4 and Week 8 ] [ Designated as safety issue: No ]
    This 20-item scale assesses two components of mindfulness, acceptance and awareness. Total scores on both subscales range from 20 to 100, higher scores reflect greater mindfulness. The PHLMS will be collected at baseline, during week 4 and post- intervention.

  • Exit Survey [ Time Frame: Week 8 ] [ Designated as safety issue: Yes ]
    Participants will complete a brief survey regarding their experience with the yoga class. The survey is comprised of open-ended and multiple-choice response items (e.g. treatment expectations).

  • Practice Log [ Time Frame: once a week for a total period of 8 weeks ] [ Designated as safety issue: Yes ]
    Participants will be asked to complete a weekly log online to report the activity performed, time allotted to the practice and will be used to evaluate compliance.


Enrollment: 0
Study Start Date: June 2012
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Yoga
Yoga group
Behavioral: Yoga Intervention
Three yoga classes per week for 8 weeks.
Other Name: Yoga, Ashtanga

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18+
  • Diagnosis of ocular hypertension not requiring treatment of IOP
  • IOP in at least one eye ≥ 21 mm Hg
  • Normal Humphrey 24-2 or 30-2 visual fields for both eyes as determined by the patient's glaucoma specialist
  • Best-corrected visual acuity better than 20/40 in both eyes
  • Being healthy to the extent that participation in yoga therapy would not exacerbate any existing disease conditions;
  • Participants do not engage in athletic activity on a regular basis (i.e. are sedentary)
  • Able and willing to participate on a weekly basis for the 11-week intervention;
  • Informed consent

Exclusion Criteria:

VISUAL HISTORY

  • Any visual field loss in either eye consistently detected with Humphrey Visual Field 30-2 or 24-2
  • Inability to understand study procedures or communicate responses to visual stimuli in a consistent manner (cognitive impairment)
  • Previous intraocular surgery, except for uncomplicated extracapsular cataract extraction with posterior chamber-intraocular lens implant and no escape of vitreous to the anterior chamber, strabismus, cosmetic eyelid surgery, and radial keratotomy
  • Secondary causes of elevated IOP, including ocular and systemic corticosteroid use
  • Angle closure glaucoma or anatomically narrow angles—75% of the circumference of the angle must be grade 2 or more by Shaffer criteria
  • Pigmentary glaucoma
  • Congenital glaucoma
  • Other diseases that cause visual field loss or optic disc abnormalities
  • Difference in cup-disc ratios (horizontal by contour) between the two eyes of >0.2
  • Background diabetic retinopathy, defined as at least 1 microaneurysm seen on ophthalmoscopy with dilated pupil, or any retinal hemorrhage

SPECIFIC SYSTEMIC DISEASES/CONDITIONS

  • Abdominal Aneurism
  • Cancer, metastatic
  • Fibromyalgia, severe
  • Inflammatory autoimmune diseases (e.g. Lupus, Rheumatoid arthritis, Scleroderma)
  • Other disabling chronic conditions (e.g., disabling heart or lung disease, diabetic neuropathy, receiving treatment for hepatitis)
  • A life-threatening or debilitating disease

BACK PROBLEM OF COMPLICATED NATURE, INCLUDING MEDICO-LEGAL ISSUES

  • Seeking/receiving compensation/litigation for back pain
  • Previous back surgery, ever
  • Low back pain that has lasted > 1 month
  • Severe pain when bending or twisting spine
  • Sciatica
  • Discitis or Disk disease
  • Fracture of vertebra
  • Infectious cause of back pain
  • Scoliosis, severe or progressive
  • Spinal stenosis
  • Spondylolisthesis
  • Anklyosing spondylitis

CONDITIONS THAT MIGHT MAKE IT DIFFICULT TO ATTEND THE CLASSES OR PRACTICE AT HOME.

  • Deafness or severe hearing problems
  • Psychoses, major
  • Schedules do not permit participation in classes or home practice (including planning to move out of town)
  • Paralysis
  • Unable to walk two city blocks
  • Unable to get up and down from floor
  • Lack of transportation
  • Any planned surgery during the upcoming study period

CONDITIONS/CIRCUMSTANCES THAT MIGHT CONFOUND TREATMENT EFFECTS OR INTERPRETATION OF DATA

  • Pregnant or nursing women as determined by patient self-report
  • Use of psychotropic medication
  • Consumption of more than three alcoholic beverages per day
  • Smoking more than 10 cigarettes per day
  • Recent substance abuse

CONDITION WOULD MAKE IT DIFFICULT TO PROVIDE FULLY INFORMED CONSENT

  • Dementia
  • Long or short-term memory loss
  • Unable to read or speak English
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01446588

Locations
United States, Maryland
Lions Vision and Research Rehabilitation
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Ava Bittner, OD, PhD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Pamela Jeter, Postdoctoral Research Fellow, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT01446588     History of Changes
Other Study ID Numbers: NA_00041019
Study First Received: September 20, 2011
Last Updated: May 23, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Anxiety Disorders
Depression
Depressive Disorder
Hypertension
Ocular Hypertension
Sleep Disorders
Dyssomnias
Parasomnias
Mental Disorders
Behavioral Symptoms
Mood Disorders
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on August 26, 2014